News Medical on MSN5d
Gene therapy breakthrough offers hope for severe Dravet syndrome casesAAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of ...
A team of researchers has developed a new gene therapy for children with Dravet syndrome - a rare type of epilepsy in ...
Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...
News Medical on MSN8d
Gene therapy shows promise in treating SCN1B-linked epileptic encephalopathiesDravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of symptoms in children, including seizures, intellectual disability, and even ...
Michigan Medicine researchers have developed a SCN1B gene therapy that restores brain function and survival in mice with ...
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...
The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...
Recent research takes aim at the a variant in gene SCN1B, which causes a severe form of developmental epileptic encephalopathy. Dravet syndrome and other developmental epileptic encephalopathies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback